Nyxoah (NASDAQ:NYXH – Get Free Report) and 10x Genomics (NASDAQ:TXG – Get Free Report) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, valuation, earnings, profitability and analyst recommendations.
Valuation and Earnings
This table compares Nyxoah and 10x Genomics”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Nyxoah | $11.33 million | 10.26 | -$101.92 million | ($2.68) | -1.12 |
| 10x Genomics | $642.82 million | 4.43 | -$43.54 million | ($0.35) | -63.66 |
Institutional & Insider Ownership
84.7% of 10x Genomics shares are held by institutional investors. 10.0% of 10x Genomics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Profitability
This table compares Nyxoah and 10x Genomics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Nyxoah | -884.69% | -139.18% | -79.53% |
| 10x Genomics | -6.77% | -6.89% | -5.34% |
Analyst Recommendations
This is a summary of recent ratings and target prices for Nyxoah and 10x Genomics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Nyxoah | 1 | 0 | 3 | 0 | 2.50 |
| 10x Genomics | 2 | 9 | 5 | 1 | 2.29 |
Nyxoah presently has a consensus target price of $9.33, suggesting a potential upside of 211.11%. 10x Genomics has a consensus target price of $20.82, suggesting a potential downside of 6.55%. Given Nyxoah’s stronger consensus rating and higher possible upside, analysts clearly believe Nyxoah is more favorable than 10x Genomics.
Risk and Volatility
Nyxoah has a beta of 1.66, meaning that its share price is 66% more volatile than the S&P 500. Comparatively, 10x Genomics has a beta of 2.17, meaning that its share price is 117% more volatile than the S&P 500.
Summary
10x Genomics beats Nyxoah on 11 of the 15 factors compared between the two stocks.
About Nyxoah
Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
About 10x Genomics
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell. The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
Receive News & Ratings for Nyxoah Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nyxoah and related companies with MarketBeat.com's FREE daily email newsletter.
